Compare AbCellera Biologics Inc (ABCL) vs Vanguard Mega Cap Growth ETF (MGK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Vanguard Mega Cap Growth ETF — how do they compare? AbCellera Biologics Inc trades at $7.26 (market cap $2.35B), while Vanguard Mega Cap Growth ETF trades at $86.22. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, Vanguard Mega Cap Growth ETF nearer its low. Which is the better fit depends on your goals.
| ABCL | MGK | |
|---|---|---|
Market Cap | $2.35B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $8.12 | $92.06 |
52-Week Low | $2.78 | $70.70 |
Enterprise Value | $1.99B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
MGK trades at $88.29, up 1.47% today, with a bullish technical signal from moving averages but bearish oscillators. The ETF completed a 1:5 stock split in April 2026 and announced a $0.08 dividend for H1-2026. News highlights potential inclusion of SpaceX and emphasizes MGK's low 0.05% expense ratio and heavy concentration in mega-cap tech stocks, which have driven historical outperformance versus the S&P 500.
Outlook remains positive due to exposure to high-growth tech giants, though concentration risk and overbought technicals near-term pose challenges. Long-term growth potential is supported by earnings momentum, but investors face volatility from sector rotations and valuation sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Vanguard Mega Cap Growth ETF
MGK is an ETF that seeks to track the performance of the CRSP US Mega Cap Growth Index. It provides a low-cost, diversified exposure to the largest growth companies in the U.S. stock market. The fund is composed of mega-cap stocks that exhibit key growth factors, including high expected long-term earnings growth, high historical sales and earnings growth, and high return on assets. MGK is typically used by investors seeking long-term capital appreciation from market-leading firms.
Read more on MGK →
